Velius In The News
Velius Announces an Expansion of Its Scientific Advisory Board
Velius, LLC, today announced the expansion of its Scientific Advisory Board, composed of leading medical professionals in the fields of dermatology, animal health and biopolymer chemistry.
The Scientific Advisory Board helps advance Velius' mission to evolve, innovate and create new intellectual property from its nanofilm technology . This technology is currently used in its patented scar repair and dermatology products. Velius currently holds 5 U.S. patents as well as multiple trademarks and has patents issued in 25 other countries across the globe. Board members will assist the management team with assessing technology options, developing new IP, and providing expertise on future clinical trends.
The company has developed a large suite of pharmaceutical products for the treatment of various skin diseases, including its flagship OTC products, Scarguard and Bruiseguard. Its OTC products are sold in most major pharmacy chains in North America.
Velius has developed patented prescription drugs to fill voids in the current therapeutic offerings for psoriasis, eczema and cutaneous scarring. The company is also currently pioneering novel prescription medicines to treat several other serious diseases and is filing patents on new formulations and applications. All are a testament of its continued growth within the biopharmaceutical industry. With these new additions to its Scientific Advisory Board, Velius foresees even greater opportunities.
"The Scientific Advisory Board is essential to our future success because the application of solid science has always been the basis for the development and deployment of our innovative technology," said Dr. Joel Studin, Founder and CEO of Velius. "The Board's guidance and extraordinarily deep insight into varied, yet related areas will contribute greatly to our scientific advancements while ensuring that our products meet Velius' global customer needs."
The new additions to its Scientific Advisory Board are:
Richard D. Granstein, M.D.
Richard D. Granstein, M.D. is the George W. Hambrick, Jr. Professor and Chairman of the Department of Dermatology at the New York Weill Cornell Medical Center of New York-Presbyterian Hospital. Dr. Granstein obtained his undergraduate education at the Massachusetts Institute of Technology and his medical education at the UCLA School of Medicine. After completing his internship in 1979, he trained in dermatology at the Massachusetts General Hospital. As a Research Fellow, Dr. Granstein studied immunology and tumor biology at the National Cancer Institute-Frederick Cancer Research Facility and at Harvard Medical School. Dr. Granstein joined the faculty of the Department of Dermatology at Harvard Medical School and the Massachusetts General Hospital in 1984. In 1995 he left Harvard to become Chairman of the Department of Dermatology at the Weill Medical College of Cornell University and Dermatologist-in-Chief at the New York Weill Cornell Medical Center of New York-Presbyterian Hospital. Dr. Granstein's research interests center on the regulation of immunity within the skin and the relationship of the skin's immune system to the development of skin cancers. He also has a special research interest in the regulation of the immune system by stress and the nervous system. He was the first to demonstrate that certain immune cells within the skin are capable of initiating an immune response against a malignant tumor and that immune cells within the epidermis (the upper layer of the skin) have an anatomic relationship with nerves and can be regulated by proteins produced by those nerves. His clinical interests include autoimmune disorders of the skin, skin cancer, and psoriasis.
Robert K. Prud'homme, PhD
Robert K. Prud'homme is a professor in the Department of Chemical and Biological Engineering at Princeton University and Director of the Engineering Biology Program. He received his BS at Stanford University and his PhD from the University of Wisconsin at Madison under Professor Bob Bird. He has served on the executive committees of the American Institute of Chemical Engineers Materials Science Division and the U.S. Society of Rheology and was the President of the U.S. Society of Rheology. He has served as the chair of the Technical Advisory Board for Material Science Research for Dow Chemical Company, which directs Dow's materials research programs, and he was on the Board of Directors of Rheometric Scientific Inc., the leading manufacturer of rheological instrumentation. He also served on the Nanotechnology Scientific Advisory Committee for BASF, which provided guidance for future trends in nanotechnology for the company. His awards include the NSF Presidential Young Investigator Award, Princeton School of Engineering and Applied Science Outstanding Teaching Award, the Sydney Ross Lectureship at RPI, the Bird,Stewart and Lightfoot Lecturer at the University of Wisconsin, the Dinesh Shah lectureship at the University of Florida, and the Midland Macromolecular Institute Visiting Professor in Midland Michigan. He has been the organizer and Chair of the Gordon Conference on Ion Containing Polymers, and the Society of Petroleum Engineers Forum on Stimulation Fluid Rheology, in addition to organizing numerous sessions at AIChE, ACS, and SOR meetings. He directed the Princeton-University of Minnesota-Iowa State NSF NIRT Center on nanoparticle formation. His research interests include rheology and self-assembly of complex fluids. Systems of interest are biopolymer solutions and gels, surfactant mesophases, and polymer/surfactant mixtures. The goals of the studies are to understand how weak molecular-level interactions can be used to tune macroscopic bulk properties and phase behavior. Application of the work is directed at nanoparticle formation for the drug delivery, controlled release, targeting, and imaging.
James G. Krueger, M.D., PhD
Dr. Krueger, M.D., PhD is a Professor of Dermatology at Rockefeller University. Dr. Krueger received his bachelor's degree from Princeton University in 1979, his Ph.D. from The Rockefeller University in 1984 and his M.D. from Cornell University Medical College in 1985. He came to Rockefeller as a guest investigator in the Laboratory for Investigative Dermatology, was appointed assistant professor in 1990, associate professor and head of lab in 1995 and professor in 2003. Dr. Krueger has held positions at The Rockefeller University Hospital since 1989. In 2006 he became co-director of the Center for Clinical and Translational Science, established by a Clinical and Translational Science Award from the National Center for Research Resources of the National Institutes of Health. Dr. Krueger was medical director and program director of the General Clinical Research Center from 1996 to 2006 and currently directs the Milstein Medical Research Program, which conducts new clinical studies of the pathogenesis of melanoma and other pigmentory diseases. In 2010 Dr. Krueger won the Astellas Award in Public Health from the American Academy of Dermatology as well as the Farber Award from the Society of Investigative Dermatology. In 2006 Dr. Krueger received the E.H. Ahrens Jr. Award for clinical research from the Association for Patient-Oriented Research. He is also a recipient of two awards from the American Skin Association: the Distinguished Achievement Award and the Psoriasis Research Achievement Award, both granted in 2001. Dr. Krueger is a member of the American Society for Clinical Investigation and the Association of American Physicians.
Drore Eisen, M.D.
Drore Eisen is a dual trained dermatologist and dentist with expertise in diseases of the oral cavity. He received his B.A. from Columbia University, dental and medical degrees from the Medical College of Virginia and completed his dermatology training at the University of Michigan where he served as chief resident. He has authored 2 textbooks which have received accolades in many peer reviewed medical and dental publications, several chapters in textbooks and over 50 articles on oral and medical diseases including publications in The New England Journal of Medicine and The Lancet. Drore has been an invited and featured speaker at numerous major medical and dental conferences and a visiting lecturer at many universities, both nationally and internationally. He is the recipient of the prestigious Harold O. Perry Lecture Award, Mayo Clinic. He has also served as a principal investigator or co-investigator in over 50 clinical trials with many large pharmaceutical companies and collaborated on oral cancer research projects with The National Cancer Institute.
For more information about Velius, log on to https://veliuspharm.com.
Read the story on StreetInsider.com
Velius, LLC Announces the Initiation of Animal Studies for ScarFilm Rx and Psoriafilm Rx for Scars and Psoriasis While Simultaneously Filing Two FDA 510(k) Applications.
(June 12, 2014 Great Neck, N.Y.) Velius, LLC today announced the initiation of mini-pig animal studies in California. These studies will be on two of their proprietary prescription drugs, Scarfilm Rx and Psoriafilm Rx. Both these drugs use the Company’s patented topical nanofilm technology to treat scars and psoriasis. Simultaneously with these animal studies, Velius is filing two new 510(k) applications with the FDA.The mini-pig animal studies will cover various levels of potency for each of the two drugs. The primary objective of these studies will be to provide evidentiary data for FDA applications showing cytokine and enzymatic response to the Company’s drugs. Velius plans to have the skin-punch biopsies from the studies analyzed by experts at Rockefeller University. These analyses will demonstrate the bioactivity of the drugs at the cellular level along the timeline of therapy.Following the completion of these animal studies, Velius will conduct similar confirmatory human studies. The skin-punch biopsies from these studies will also be analyzed by Rockefeller University to provide a full dataset of both animal and human results.The 510(k) FDA applications are the first two in a series of a total of six applications that Velius intends to file over the next eighteen months.Velius’ Scarfilm Rx is a potent topical combination drug that shrinks hypertrophic (raised) or keloid scars. Several clinical studies and decades of clinical practice have shown that multiple intracutaneous injections of corticosteroids into scars are effective in reducing scar tissue. Corticosteroid injections into newly-formed or legacy scars are excruciatingly painful and therefore few patients accept this mode of repeated treatment. Scarfilm Rx, through its proprietary paint-on nanofilm technology, provides nearly the same bioavailability as a subcutaneous injection in the form of a painless topical treatment. This will encourage many more patients to treat unsightly legacy scarring. It will also offer a potent option for post-surgery and post-injury prophylaxis in people prone to keloid and hypertrophic scarring. The number of new scars formed each year from accidents and surgeries, in addition to the number of legacy scars is enormous. Scarfilm Rx’s easy application and nearly invisible properties will greatly enhance patient acceptance and compliance. Scarfilm Rx has the added advantage that it is less than 1 micron thick, so if used on the face, make-up can be placed over it.Psoriasis is a dermatological disease affecting more than 3% of the global population. Velius’ Psoriafilm Rx is a potent topical psoriasis combination drug that has shown in tests to ease the symptoms of psoriasis more rapidly than current topical medications. Psoriafilm Rx has the unique ability to enhance penetration of medications into psoriatic plaques, giving it a major advantage over gels, creams, sprays and ointments. These older vehicles have difficulty penetrating psoriatic plaques, limiting their effectiveness. In addition, the occlusive properties of Psoriafilm Rx provide nearly instant relief of pain and itching. Its biomechanical integration with the surface architecture of the psoriatic plaque ensures that it does not rub off or wash off. This allows the medicine to keep working reliably 24/7. The film eventually flakes off with the psoriatic plaque, leaving a healed skin surface.Velius believes that Psoriafilm Rx will be greatly favored by both doctors and patients. Its mode of treatment is significantly less threatening than subcutaneous hypodermic or intravenous injections of corticosteroids, monoclonal antibodies or anti-TNF alpha drugs while at the same time being much more effective than gels, creams, ointments or sprays. Its side effect profile is substantially less than the monoclonal antibodies or anti-TNF alpha drugs. Its treatment regimen costs less and is safer. As a result, insurers are more likely to place Psoriafilm Rx into a mandatory treatment algorithm for psoriasis before advancing to more dangerous alternatives. The drug will also be effective for many types of eczema.Velius expects that the commencement of these animal studies combined with the two FDA application submissions will have a rapid and positive impact on its valuation as it moves its drugs through the FDA approval process.
About Velius LLC
Velius, LLC, is a global biopharmaceutical company focused on the translation of innovative science into treatment. The company currently offers products and services for the treatment and management of skin diseases, and is pioneering novel medicines in areas of other serious disease areas. Velius’ goal is to address some of today’s most pressing areas of unmet medical need. The Company has developed a large pipeline of OTC and Prescription drugs and is currently filing patents on new formulations and applications. The Company also sells its OTC products in most major drugstores in North America under the Brand names Scarguard and Bruiseguard. Some of these OTC products are distributed by a major Pharmaceutical company in Asia. For more information, visit www.veliuspharm.com and www.scarguard.com.
This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Velius expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Peter Mills, CFO
Nanopatch Trademark Issued
The world that we live in is full of gadgetry that our great grandparents would think could only exist in a science fiction book. Nanotechnology has been the springboard for many of these advances. Computers that used to fill buildings, fit into a watch, nano-particles such as Graphene provide amazing coatings one atom thick, and everything from tennis racquets to jumbo jets are lighter and stronger. The field of Nanotechnology has sparked advances in medicine as well. Many medical treatments required painful injections. Others forced patients to wear unsightly patches, advertising their use. Velius is a pharmaceutical company that has developed and commercialized proprietary technology to replace painful injections and unsightly patches with a clear, virtually invisible patch that paints on less than one micron thick. This Nanopatch has been the basis for the several million units of Scarguard sold and for many new prescription drugs in the areas of psoriasis, eczema, keloid scarring and animal health.For further information please contact: